Neuroscience

Lilly Launches Digital Obesity, Migraine, Diabetes Management Platform

January 5, 2024 - Yesterday, January 4, 2024, Eli Lilly and Company issued a press release announcing the launch of LillyDirect. The platform is a digital healthcare tool for managing and supporting patients with obesity, migraine, and diabetes in the United States. According to the release, LillyDirect offers multiple services for disease management, support, and...

Read More


More Articles

FDA Publishes Drug Safety Communication for Antiseizure Drugs

by Veronica Salib

Earlier this week, the United States Food and Drug Administration (FDA) published a drug safety communication warning patients about potentially life-threatening side effects linked to levetiracetam...

FDA Clears IND for New Parkinson’s Disease Treatment Using IPSCs

by Veronica Salib

Today, Aspen Neuroscience announced that the United States Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for a new Parkinson’s Disease gene...

Top 10 Myths About Medicinal and Recreational Cannabis

by Alivia Kaylor

Addressing the top 10 most common myths about medicinal and recreational cannabis is critical to promote informed decision-making, reduce stigma, and foster evidence-based discussions, leading to safer use and better public policies....

Top 3 Use Cases for Psychedelics, Understanding Ongoing Research

by Veronica Salib

Throughout the past decade, psychedelics have become a primary area of interest for ongoing clinical research. Scientists have hypothesized multiple clinical use cases for these medications despite primarily being scheduled or illicit...

Melanoma Drugs Repurposed Can Shrink Rare Brain Tumors

by Veronica Salib

A study published last week in the New England Journal of Medicine concluded that BRAF–MEK inhibitors — traditionally used in melanoma treatment — can shrink papillary...

Biogen and Eisai Secure Traditional FDA Approval for Lequembi

by Veronica Salib

On July 6, 2023, the FDA granted Biogen Inc and Eisai Co’s Lequembi traditional FDA approval. The approval was based on a supplemental Biologics License Application (sBLA) and prior accelerated...

Men in the US Are More Likely to Have a Fatal Overdose Than Women

by Veronica Salib

As the opioid epidemic in the United States continues to progress, a recent study revealed that men are more likely to have a fatal overdose than women. Data from a study — led by researchers...

Sleeping Pills Linked to Lower Levels of Alzheimer’s Disease Proteins

by Veronica Salib

A recent study published in the Annals of Neurology identified a link between sleeping pill use and lowered levels of Alzheimer's disease protein. Protein buildups and plaques identified in...

CDC Analyzes Sleep Medication Usage by Adults in the United States

by Veronica Salib

A recent National Center for Health Statistics (NCHS) analysis determined that 18.4% of adults in the United States took a sleep medication to fall or stay asleep in the past 30 days. The study...

FDA Accelerates Approval of a New Alzheimer’s Disease Drug, Leqembi

by Veronica Salib

Based on the results of a double-blind, placebo-controlled, the FDA granted the accelerated approval of Leqembi for Alzheimer’s disease, making it the second approved medication targeting the...

Initiating Dementia Treatment, Pharmacological Interventions

by Veronica Salib

The WHO notes that approximately 55 million people in the world have dementia. Considering the rate of aging and the complications that coincide with aging, Alzheimer's Disease International anticipates that the number of people with...

Adderall Withdrawal Exacerbated by Pharmaceutical Supply Chain Issues

by Veronica Salib

On October 12, 2022, the FDA announced a shortage of Adderall and Adderall IR. These shortages have exacerbated withdrawal symptoms and left patients struggling to manage their ADHD by rationing their medication. Understanding how...

A Single Dose of Psilocybin Can Reduce MADRS Score

by Veronica Salib

BMC Psychiatry states that up to one-third of patients with major depressive disorder become resistant to treatment, otherwise known as treatment-resistant depression. In recent years, psilocybin and...

Bridging Surgical Treatment and Chemoradiation for Glioblastoma Patients

by Veronica Salib

On October 11, 2022, GT Medical announced the first participant enrolled in the GammaTile Enhanced Stupp ALTernative (GESTALT) trial. While this trial is still in its infancy, if the results are favorable, it may influence protocols for...

Diversifying Clinical Trials through Telehealth Platforms

by Veronica Salib

In a recent press release, Ro — a healthcare company — announced that it will partner with the National Institute of Aging, a subset of the NIH, to use its telehealth platform to diversify...

Combining Existing Drugs Introduced New Parkinson’s Disease Treatment

by Veronica Salib

The National Institute of Neurological Disorders and Stroke, a subset of the NIH, estimates that nearly one million people in the United States have Parkinson’s disease. Considering the ever-aging population and the increased risk of...

FDA and NIH Launch Partnership for Rare Neurodegenerative Diseases

by Veronica Salib

Earlier this week, the FDA and NIH announced their launch of a public–private partnership for research on rare neurodegenerative diseases. The partnership, called the Critical Path for Rare...

Psilocybin-Assisted Psychotherapy Reduces Heavy Drinking

by Veronica Salib

Psilocybin, a chemical compound derived from mushrooms, has been a topic of interest for researchers focused on neuropsychiatric conditions, specifically substance use disorders. A double-blind,...

Glucocorticoids Alter Brain Volume and White Matter Microstructure

by Veronica Salib

Glucocorticoids are widely prescribed for those struggling with autoimmune and neurological conditions and are considered one of the most prescribed drugs. In a study published in BMJ Open, researchers...

Recent Articles